[Federal Register Volume 67, Number 150 (Monday, August 5, 2002)]
[Notices]
[Page 50651]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 02-19714]


-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Department of the Army


Availability for Non-Exclusive, or Partially Exclusive Licensing 
of U.S. Patent Application Concerning Chimeric Filovirus Glycoprotein

AGENCY: Department of the Army, DOD.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: In accordance with 37 CFR 404.6 and 404.7, announcement is 
made of the availability for licensing of U.S. Patent Application No. 
10/066,506 entitled ``Chimeric Filovirus Glycoprotein,'' filed January 
31, 2002. Foreign rights are also available (PCT/US02/03339). The 
United States Government, as represented by the Secretary of the Army 
has rights in this invention.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, 
ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, 
Frederick, MD 21702-5012.

FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth 
Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul 
Mele, Office of Research & Technology Assessment, (301) 619-6664, both 
at telefax (301) 619-5034.

SUPPLEMENTARY INFORMATION: Chimeric GP molecules were constructed which 
contain portions of both the EBOV and MBGV GP proteins by swapping the 
subunits between EBOV and MBGV. The chimeric molecules were cloned into 
an alphavirus replicon, which offers the advantage of high protein 
expression levels in mammalian cells and is a proven vaccine vector. 
These chimeric molecules fully protected guinea pigs from MBGV 
challenge, and conversely protected the animals from EBOV challenge. 
These results indicate that a protective epitope resides within the GP2 
submit of the MBGV GP protein and at least partially within the GP2 
subunit of the EBOV GP protein. Additionally these results show that a 
construction of a single-component bivalent vaccine protective in 
guinea pigs is achievable.

Luz D. Ortiz,
Army Federal Register Liaison Officer.
[FR Doc. 02-19714 Filed 8-2-02; 8:45 am]
BILLING CODE 3710-08-M